key: cord-0810791-qqr6drip authors: Papadopoulos, Konstantinos I.; Sutheesophon, Warachaya; Aw, Tar-Choon title: The influence of renin angiotensin aldosterone system (RAAS), endothelial nitric oxide synthase (eNOS) and erythropoietin (EPO) on COVID-19 complications date: 2022-01-26 journal: Chem Biol Interact DOI: 10.1016/j.cbi.2022.109834 sha: f2e9d1a166a36647093806ad2b189abaa1fad36b doc_id: 810791 cord_uid: qqr6drip Certain aspects of the renin-angiotensin-aldosterone system (RAAS) have eluded deserved attention such as the role of erythropoietin (EPO) and nitric oxide (NO) both of which appear to significantly modulate COVID-19 disease course. Furthermore, renin-angiotensin-aldosterone system (RAAS) and endothelial NO synthase (eNOS) genetic polymorphisms additionally impact on EPO and NO homeostasis and have extensive implications on pharmacological disease management.  EPO is regulated not only by hypoxia or anemia but also by RAAS and its genetic 23 polymorphisms.  Endothelial nitric oxide (NO) synthase (eNOS) activity in endothelium mediates EPO 25 effects.  Increased NO-generation and bioavailability inhibits SARS-CoV-2 ACE2 binding.  eNOS genetic variants alter NO-generation and bioavailability and may modulate 28 COVID-19 course.  EPO oversecretion appears protective against SARS-CoV-2 infection in children and 30 young adults. An evolution-congruent strategy, restoring the integrity of the RAAS-EPO pathway and 118 endogenous EPO secretion as well as supporting a healthy NO-generation by using EPO-119 neutral antihypertensive treatments, NO donor modalities, fluvoxamine/fluoxetine, statins 120 while concurrently employing rhEPO and/or EPO analogs will break this vicious circle of 121 RAAS hyperstimulation. 2, 18, 20, 25, 26 Knowledge of patients' genetic status regarding RAAS and 122 eNOS polymorphisms as well as awareness of their pharmacogenetic implications in 123 cardiovascular drug therapy along with recognition of AT1-AA presence will help decide 124 which pharmacological interventions will benefit which patient groups best. The most potent 125 Ang II type 1 receptor blocker, olmesartan, significantly increased NO generation by 30% in 126 all eNOS polymorphic variants but especially in the homozygous minor variant genotypes 127 894TT/786CC. 27 Novel compounds like NP-6A4 appear as an ideal adjuvant drug candidate 128 for EPO mediated tissue protection and mitigation of cytokine storm. 28 Future research Increased complications of COVID-19 in people with 143 cardiovascular disease: Role of the renin-angiotensin-aldosterone system (RAAS) dysregulation Age and Genotype Dependent 146 Erythropoietin (EPO) Protection in COVID-19 Fludrocortisone stimulates erythropoietin production in 148 the intercalated cells of the collecting ducts Effects of Angiotensin II on Erythropoietin Production 150 in the Kidney and Liver Age-related pattern and monocyte-acquired haemozoin 152 associated production of erythropoietin in children with severe malarial anaemia in Ghana Age-related changes in adaptation to 155 severe anemia in childhood in developing countries High levels of erythropoietin are associated with 157 protection against neurological sequelae in African children with cerebral malaria Alteration of L-Dopa decarboxylase expression in 160 SARS-CoV-2 infection and its association with the interferon-inducible ACE2 isoform beta Common receptor integrates the erythropoietin 163 signaling in activation of endothelial nitric oxide synthase SARS-CoV-2 Spike Protein Impairs Endothelial Function via 165 Downregulation of ACE 2 Mitigation of the replication of SARS-CoV-2 by nitric 167 oxide in vitro Palmitoylation of SARS-CoV-2 S protein is essential for viral 169 infectivity Nephroprotection through the Akt/eNOS pathway by 171 centrally administered erythropoietin in a rat model of fixed-volume hemorrhage Neonatal and Children's Immune System and COVID-19: Biased Immune Tolerance 174 versus Resistance Strategy Converting Enzyme Gene Polymorphism Is Associated with Anemia in Non-Small-Cell Lung Cancer Endothelial Nitric Oxide Synthesis and Renin-Angiotensin-Aldosterone System with Developing of 180 Multi-locus interactions of vascular homeostasis genes 182 in essential hypertension: a gender-based study System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in 185 Diabetes Clinically relevant 187 endothelial nitric oxide synthase polymorphisms and their impact on drug response Endothelial Dysfunction in Chronic Kidney Disease, 190 from Biology to Clinical Outcomes: A 2020 Update Cardiovascular Interactions between Fibroblast Growth Factor-23 192 and Soluble Angiotensin Converting Enzyme 2 194 (ACE2) Is Upregulated and Soluble Endothelial Nitric Oxide Synthase (eNOS) Is Downregulated in 195 COVID-19-induced Acute Respiratory Distress Syndrome (ARDS) Further Observations on Pregnancy Complications 198 and COVID-19 Infection Functional autoantibodies against G-protein 200 coupled receptors in patients with persistent Long-COVID-19 symptoms Anti-SARS-CoV-2 Action of Fluvoxamine may be 203 Mediated by Endothelial Nitric Oxide Synthase Addressing the 'hypoxia paradox' in severe 205 COVID-19: literature review and report of four cases treated with erythropoietin analogues Effects of angiotensin receptor blockers on endothelial 208 nitric oxide release: the role of eNOS variants Suppression of Inflammatory Cardiac Cytokine 210 Network in Rats with Untreated Obesity and Pre-Diabetes by AT2 Receptor Agonist NP-6A4. Front of renin angiotensin aldosterone system (RAAS), endothelial nitric oxide synthase (eNOS) and erythropoietin (EPO) on COVID-19 complications